Search 

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)

Strategy, Management and fundraising for genomic companies. Invest and help raise capital through private and public placements in the US, as well as guide company executives on Operational execution in the molecular diagnostics industry.